

Publications auxquelles l'Aretasc a participé en 2020

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau
Philipp Harter, Florence Joly, for the AGO-OVAR 2.21/ENGOT-ov 18
Investigators*
16 April 2020 : Lancet Oncology

Overestimation of Late Distant Recurrences in high-risk patients with ER-Positive Breast Cancer ; Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. J Clin Oncol 38. © 24 July 2020 by American Society of Clinical Oncology

GCO CACOVID : The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management Esmo 16-19 September 2020

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (*GCO-002 CACOVID-19*) dans l'**European Journal of Cancer** (Décember 2020).

Rx Ponder Clinical Trial Design.

Swog S1007 : adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.
Virtual San Antonio Breast Cancer Symposium December 10, 2020